Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential
ACS Medicinal Chemistry Letters September 15, 2023 DOI: 10.1021/acsmedchemlett.3c00390 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Psilocybin MDMA |
| Topics | Serotonin |
| Keywords | Tryptamines 5-HT Receptor Pharmacology Data science |
| Citations | 11 |
| Key findings | Tryptamines show potential for mental health therapy, with clinical trials indicating significant improvements in patient-reported outcomes via reductions in experiential avoidance. |
Abstract
Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has granted "breakthrough therapy designation" to psilocybin and MDMA for treatment-resistant depression, major depressive disorder, and post-traumatic stress disorder, sparking global research efforts. Various clinical trials are currently investigating the therapeutic value of psilocybin for several mental health disorders. Results thus far indicate significant improvements in patient-reported outcomes via reductions in experiential avoidance. These advancements highlight a promising future for tryptamines in mental health therapy.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cited by 5
- Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms Angewandte Chemie International Edition September 21, 2025
- Psychedelic fungi Current Biology June 1, 2025
- Continuous flow synthesis of N,N-dimethyltryptamine (DMT) analogues with therapeutic potential. RSC Medicinal Chemistry October 7, 2024
- Unlocking the power of tryptamine alkaloids in Psilocybe fungi: chemistry, mental health potential and legal challenges Mycological Progress December 8, 2025
- Unterschiedliche Reaktionen und Enzyme in der Psilocybin‐ Biosynthese bei Inocybe‐ und Psilocybe ‐Pilzen Angewandte Chemie September 21, 2025
Cites 5
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review Journal of Psychopharmacology July 1, 2023
- Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants Pharmacological Research June 26, 2023
- Role of Psychedelics in Treatment-Resistant Depression. Psychiatric Clinics of North America June 1, 2023
- Experiences of psilocybin treatment for clinical conditions: A qualitative meta‐synthesis International Journal of Mental Health Nursing February 13, 2023